Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy

T. Caraceni, E. A. Parati, F. Girotti, Ivana Celano, Clara Frigerio, Daniela Cocchi, E. E. Müller

Research output: Contribution to journalArticlepeer-review

Abstract

In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.

Original languageEnglish
Pages (from-to)217-222
Number of pages6
JournalPsychopharmacology
Volume63
Issue number3
DOIs
Publication statusPublished - Jan 1979

Keywords

  • Behavioral effects
  • Growth hormone
  • l-dopa
  • MIF-I
  • Parkinson's disease
  • Prolactin

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy'. Together they form a unique fingerprint.

Cite this